John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background and purpose: Infection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. Methods: Natalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. Results: One hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. Conclusions: Higher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients.

Original languageEnglish
Pages (from-to)1196-1199
Number of pages4
JournalEuropean Journal of Neurology
Volume24
Issue number9
DOIs
Publication statusPublished - 1 Sep 2017

Cite this

@article{23b286809afb4e79b9c868e49d4188c6,
title = "John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients",
abstract = "Background and purpose: Infection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. Methods: Natalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. Results: One hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. Conclusions: Higher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients.",
keywords = "JC virus, multiple sclerosis, natalizumab",
author = "{van Kempen}, {Z. L.E.} and Leurs, {C. E.} and {de Vries}, A. and A. Vennegoor and T. Rispens and Wattjes, {M. P.} and J. Killestein",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/ene.13355",
language = "English",
volume = "24",
pages = "1196--1199",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "9",

}

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients. / van Kempen, Z. L.E.; Leurs, C. E.; de Vries, A.; Vennegoor, A.; Rispens, T.; Wattjes, M. P.; Killestein, J.

In: European Journal of Neurology, Vol. 24, No. 9, 01.09.2017, p. 1196-1199.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients

AU - van Kempen, Z. L.E.

AU - Leurs, C. E.

AU - de Vries, A.

AU - Vennegoor, A.

AU - Rispens, T.

AU - Wattjes, M. P.

AU - Killestein, J.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background and purpose: Infection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. Methods: Natalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. Results: One hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. Conclusions: Higher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients.

AB - Background and purpose: Infection with the John Cunningham virus (JCV) is required for the development of progressive multifocal leukoencephalopathy, the feared complication of natalizumab treatment in multiple sclerosis patients. The JCV seroconversion rate seems higher in natalizumab treated patients than in the normal population, with an unknown cause. Methods: Natalizumab concentration was correlated to JCV antibody status and seroconversion in a large cohort of multiple sclerosis patients. Results: One hundred and thirty-five patients were included. No correlation was found between natalizumab concentration and JCV status, JCV seroconversion or JCV index. Conclusions: Higher natalizumab concentrations do not explain the increased JCV seroconversion rate in natalizumab treated patients.

KW - JC virus

KW - multiple sclerosis

KW - natalizumab

UR - http://www.scopus.com/inward/record.url?scp=85023646437&partnerID=8YFLogxK

U2 - 10.1111/ene.13355

DO - 10.1111/ene.13355

M3 - Article

VL - 24

SP - 1196

EP - 1199

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 9

ER -